Identification and Characterization of Novel Proteins and Genes in Head and Neck Cancer

This study is currently recruiting participants. (see Contacts and Locations)
Verified April 2016 by Stanford University
Sponsor:
Information provided by (Responsible Party):
Stanford University
ClinicalTrials.gov Identifier:
NCT00230308
First received: September 28, 2005
Last updated: April 14, 2016
Last verified: April 2016
  Purpose
Through this study, we hope to learn more about the mechanisms, which may contribute to development and progression of head and neck cancer. The long-term goal of this study will be to develop new strategies and drugs for the diagnosis and treatment of head and neck cancer.

Condition
Head and Neck Cancer

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: Identification and Characterization of Novel Proteins and Genes in Head and Neck Cancer

Resource links provided by NLM:


Further study details as provided by Stanford University:

Biospecimen Retention:   Samples With DNA
At the time of biospy or surgery, a small amount of tumor tissue (approximately 1 cc) will be taken from the main tumor specimen and stored until analysis.

Estimated Enrollment: 500
Study Start Date: April 2002
Estimated Study Completion Date: December 2024
Estimated Primary Completion Date: December 2019 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
All patients undergoing surgery at Stanford University for head and neck cancer.
Criteria

Inclusion Criteria:

All patients undergoing surgery at Stanford University for head and neck cancer.

Exclusion Criteria:

Non-Stanford patients.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00230308

Locations
United States, California
Stanford University School of Medicine Recruiting
Stanford, California, United States, 94305
Contact: Priya Hegde    650-723-0920    phegde@stanford.edu   
Contact: Cancer Clinical Trials Office    (650) 498-7061      
Principal Investigator: Quynh-Thu Le         
Sub-Investigator: Willard E Fee Jr         
Sub-Investigator: Zijie Sun         
Sub-Investigator: Jan Matthijs van de Rijn         
Sub-Investigator: Dr Michael Kaplan         
Sponsors and Collaborators
Stanford University
Investigators
Principal Investigator: Quynh-Thu Le Stanford University
  More Information

Responsible Party: Stanford University
ClinicalTrials.gov Identifier: NCT00230308     History of Changes
Other Study ID Numbers: ENT0008  76537  ENT0008  11402 
Study First Received: September 28, 2005
Last Updated: April 14, 2016
Health Authority: United States: Food and Drug Administration
United States: Institutional Review Board

Additional relevant MeSH terms:
Head and Neck Neoplasms
Neoplasms
Neoplasms by Site

ClinicalTrials.gov processed this record on May 04, 2016